{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:23:55Z","timestamp":1768285435933,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.canlet.2016.10.015","type":"journal-article","created":{"date-parts":[[2016,10,16]],"date-time":"2016-10-16T07:47:44Z","timestamp":1476604064000},"page":"27-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR"],"prefix":"10.1016","volume":"384","author":[{"given":"Rei","family":"Mimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoe T.","family":"Nihira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Hirooka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Takeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyotsugu","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2016.10.015_bib1","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1158\/1078-0432.CCR-04-2421","article-title":"Breast cancer molecular subtypes respond differently to preoperative chemotherapy","volume":"11","author":"Rouzier","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2016.10.015_bib2","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1158\/1078-0432.CCR-04-2402","article-title":"Dual inhibition of mTOR and estrogen receptor signaling in\u00a0vitro induces cell death in models of breast cancer","volume":"11","author":"Boulay","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2016.10.015_bib3","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes\u2013dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2016.10.015_bib4","doi-asserted-by":"crossref","first-page":"R132","DOI":"10.1186\/bcr3330","article-title":"Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in\u00a0vitro and in\u00a0vivo","volume":"14","author":"Martin","year":"2012","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2016.10.015_bib5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrm2672","article-title":"Molecular mechanisms of mTOR-mediated translational control","volume":"10","author":"Ma","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2016.10.015_bib6","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2016.10.015_bib7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.drup.2007.11.003","article-title":"Targeting the PI3K\/Akt\/mTOR pathway: effective combinations and clinical considerations","volume":"11","author":"LoPiccolo","year":"2008","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.canlet.2016.10.015_bib8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10549-013-2814-5","article-title":"Everolimus plus exemestane as first-line therapy in HR(+), HER2(-) advanced breast cancer in BOLERO-2","volume":"143","author":"Beck","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2016.10.015_bib9","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","article-title":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2dagger","volume":"25","author":"Piccart","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2016.10.015_bib10","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S1470-2045(14)70138-X","article-title":"Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"Andre","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2016.10.015_bib11","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.molcel.2007.02.007","article-title":"DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage","volume":"25","author":"Taira","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2016.10.015_bib12","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1172\/JCI60818","article-title":"DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells","volume":"122","author":"Taira","year":"2012","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.canlet.2016.10.015_bib13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.canlet.2013.06.005","article-title":"DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail","volume":"339","author":"Mimoto","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2016.10.015_bib14","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1007\/s13277-015-3264-y","article-title":"DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma","volume":"36","author":"Yamaguchi","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.canlet.2016.10.015_bib15","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/nar\/28.1.316","article-title":"TRANSFAC: an integrated system for gene expression regulation","volume":"28","author":"Wingender","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2016.10.015_bib16","doi-asserted-by":"crossref","first-page":"41600","DOI":"10.1074\/jbc.M111.240812","article-title":"Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer","volume":"286","author":"Zawacka-Pankau","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.canlet.2016.10.015_bib17","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/ncb1547","article-title":"Insulin signalling to mTOR mediated by the Akt\/PKB substrate PRAS40","volume":"9","author":"Vander Haar","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2016.10.015_bib18","doi-asserted-by":"crossref","first-page":"39505","DOI":"10.1074\/jbc.M506096200","article-title":"Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex","volume":"280","author":"Sarbassov","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.canlet.2016.10.015_bib19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0960-9822(06)00122-9","article-title":"Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha","volume":"7","author":"Alessi","year":"1997","journal-title":"Curr. Biol."},{"key":"10.1016\/j.canlet.2016.10.015_bib20","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.1162981","article-title":"FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression","volume":"321","author":"Mao","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.canlet.2016.10.015_bib21","doi-asserted-by":"crossref","first-page":"8967","DOI":"10.1158\/0008-5472.CAN-09-2190","article-title":"Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy","volume":"69","author":"Fu","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2016.10.015_bib22","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s12035-014-9028-7","article-title":"FBXW7-Induced MTOR degradation forces autophagy to counteract persistent prion infection","volume":"53","author":"Xu","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.canlet.2016.10.015_bib23","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1016\/j.bbamcr.2013.06.018","article-title":"E3 ubiquitin ligase Fbw7 negatively regulates granulocytic differentiation by targeting G-CSFR for degradation","volume":"1833","author":"Lochab","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2016.10.015_bib24","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/annonc\/mdm170","article-title":"Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling","volume":"18","author":"Beeram","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2016.10.015_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.canlet.2012.03.034","article-title":"Overcoming acquired resistance to letrozole by targeting the PI3K\/AKT\/mTOR pathway in breast cancer cell clones","volume":"323","author":"Cavazzoni","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2016.10.015_bib26","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/bcr3604","article-title":"Impact of dual mTORC1\/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in\u00a0vitro","volume":"16","author":"Jordan","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2016.10.015_bib27","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10549-015-3282-x","article-title":"In\u00a0vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response","volume":"149","author":"Hurvitz","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2016.10.015_bib28","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/1078-0432.CCR-11-2123","article-title":"PIK3CA\/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors","volume":"18","author":"Meric-Bernstam","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2016.10.015_bib29","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1111\/j.1349-7006.2012.02359.x","article-title":"Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells","volume":"103","author":"Yunokawa","year":"2012","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2016.10.015_bib30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12894-015-0040-7","article-title":"Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy","volume":"15","author":"Nomura","year":"2015","journal-title":"BMC Urol."},{"key":"10.1016\/j.canlet.2016.10.015_bib31","first-page":"2753","article-title":"DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer","volume":"29","author":"Yamashita","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.canlet.2016.10.015_bib32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.prp.2016.01.002","article-title":"Downregulated DYRK2 expression is associated with poor prognosis and Oxaliplatin resistance in hepatocellular carcinoma","volume":"212","author":"Zhang","year":"2016","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.canlet.2016.10.015_bib33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ydbio.2005.09.053","article-title":"DYRK2 and GSK-3 phosphorylate and promote the timely degradation of OMA-1, a key regulator of the oocyte-to-embryo transition in C. elegans","volume":"288","author":"Nishi","year":"2005","journal-title":"Dev. Biol."},{"key":"10.1016\/j.canlet.2016.10.015_bib34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/ncb1848","article-title":"Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3 ligase","volume":"11","author":"Maddika","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2016.10.015_bib35","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1074\/jbc.M112.416792","article-title":"Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT degradation","volume":"288","author":"Jung","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.canlet.2016.10.015_bib36","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2016.10.015_bib37","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-Kinase AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2016.10.015_bib38","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.molcel.2007.03.003","article-title":"PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase","volume":"25","author":"Sancak","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2016.10.015_bib39","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.molcel.2011.08.030","article-title":"mTOR drives its own activation via SCF(betaTrCP)-dependent degradation of the mTOR inhibitor DEPTOR","volume":"44","author":"Gao","year":"2011","journal-title":"Mol. Cell"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516306279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383516306279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T11:57:00Z","timestamp":1536321420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383516306279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":39,"alternative-id":["S0304383516306279"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2016.10.015","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2016.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}